Posted by Michael Wonder on 01 Jun 2018
EMA restricts use of Keytruda and Tecentriq in bladder cancer
1 June 2018 - Data show lower survival in some patients with low levels of cancer protein PD-L1.
Early data from two clinical trials show reduced survival with Keytruda (pembrolizumab) and Tecentriq (atezolizumab) when used as first-line treatments for urothelial cancer (cancer of the bladder and urinary tract) in patients with low levels of a protein called PD-L1. The data indicate that Keytruda and Tecentriq may not work as well as chemotherapy medicines in this group of patients.
As a result, the EMA has recommended restricting the use of these medicines as first line-treatments for urothelial cancer.
